Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · IEX Real-Time Price · USD
2.390
-0.060 (-2.45%)
At close: Jul 19, 2024, 4:00 PM
2.400
+0.010 (0.42%)
Pre-market: Jul 22, 2024, 7:22 AM EDT
Esperion Therapeutics Revenue
Esperion Therapeutics had revenue of $229.74M in the twelve months ending March 31, 2024, with 183.74% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $137.74M with 466.14% year-over-year growth. In the year 2023, Esperion Therapeutics had annual revenue of $116.33M with 54.14% growth.
Revenue (ttm)
$229.74M
Revenue Growth
+183.74%
P/S Ratio
1.77
Revenue / Employee
$957,250
Employees
240
Market Cap
407.30M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 116.33M | 40.86M | 54.14% |
Dec 31, 2022 | 75.48M | -2.97M | -3.79% |
Dec 31, 2021 | 78.45M | -149.10M | -65.52% |
Dec 31, 2020 | 227.55M | 79.18M | 53.37% |
Dec 31, 2019 | 148.36M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sonida Senior Living | 260.69M |
Cerus | 191.72M |
Anika Therapeutics | 169.26M |
AxoGen | 163.73M |
Editas Medicine | 69.41M |
C4 Therapeutics | 20.04M |
Precigen | 5.44M |
Lyell Immunopharma | 68.00K |
ESPR News
- 5 days ago - New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries - GlobeNewsWire
- 24 days ago - Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility - GlobeNewsWire
- 2 months ago - Esperion to Participate in Upcoming June Investor Conferences - GlobeNewsWire
- 2 months ago - Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia - GlobeNewsWire
- 2 months ago - Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® - GlobeNewsWire
- 2 months ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Esperion Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Esperion to Participate in Upcoming May Investor Conferences - GlobeNewsWire